Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Marsili Syndrome as a Gateway to Novel Analgesic Targets

NCT07755930 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2026-08-01
Last updated
2026-08-10

Condition(s) studied

Marsili Syndrome

Investigational drug(s) / intervention(s)

HistamineCowhage (Mucuna Pruriens)Capsaicin 8% Patch →Knee Injections of hypertonic salineCold Pressure TestComputerized Conditioned Pain Modulation (CPM)

Histamine: To deliver histamine, standard allergy skin prick test (SPT) lancets are applied

Cowhage (Mucuna Pruriens): The spicules will be manually inserted. Approximately 30-35 spicules are gently rubbed into a 1 cm diameter skin area on the forearm

Capsaicin 8% Patch: Capsaicin patches (2x2 cm, dosage form: transdermal patch 8%) will be applied on the selected area. The patch will be left in place for 30 minutes after which it will be removed.

Knee Injections of hypertonic saline: Experimental knee pain will be induced with a 0.25-0.30 mL bolus injection of 5% hypertonic saline, which will be injected into the dominant Infrapatellar Fat Pad (IFP)

Cold Pressure Test: Participants will be asked to place their hand in the cold-water tank (temperature around 5°C) and to keep it for as long as they can tolerate it.

Computerized Conditioned Pain Modulation (CPM): CPM will be assessed using a double-cuff.

Study summary

Congenital insensitivity to pain (CIP) comprises a group of rare genetic disorders caused by mutations in genes essential for pain sensing in humans. Among these, Marsili syndrome is caused by a dominant point mutation in the transcription factor ZFHX2, and it is characterized by markedly reduced sensitivity to noxious heat, mechanical injury, while other functions remain intact. this project aims to establish the first integrated, system-level characterization of Marsili syndrome by combining human sensory phenotyping with neurophysiological and molecular analyses. The study will be conducted in two sessions of approximately 4 hours each, 24 hours apart from each other

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Healthy men and women aged 18-80 years * Marsili syndrome * Speak and understand English Exclusion Criteria: * Pregnant or breastfeeding * Current regular use of cannabis, opioids, cocaine, amphetamines, MDMA/ecstasy, benzodiazepines, barbiturates, hallucinogens, or other central nervous system-active recreational drugs. * Current use of prescription medication that may significantly affect pain perception, itch perception, cortical excitability, or inflammatory responses, including opioids, antiepileptic drugs, antidepressants, antipsychotics, systemic corticosteroids, or immunosuppressive medication. * Current or previous neurological disease, including epilepsy, stroke, traumatic brain injury, spinal cord injury, multiple sclerosis, Parkinson's disease, or other degenerative neurological disorders. * Current or previous severe psychiatric disorder, including major depression, psychosis, bipolar disorder, or severe anxiety disorder. * Current or previous clinically significant musculoskeletal, cardiovascular, pulmonary, inflammatory, autoimmune, or dermatological disease that may interfere with study procedures or outcome measures. * Lack of ability to understand study information, provide informed consent, or cooperate with study procedures. * Abnormally disrupted sleep during the 24 hours before the experiment. * Contraindications to TMS, including previous epileptic seizure, implanted electronic medical devices, metal implants in the head or jaw, implanted hearing aids, facial metal implants, permanent makeup, or tattoos in the facial area. * Inability to pass the Transcranial Magnetic Stimulation Adult Safety Screen. * Abnormally disrupted sleep in the 24 hours preceding the experiment

Primary outcome measure(s)

  • Measuring pain by computerized Visual Analog Scale Scoring — Day 1
    We will ask the subjects to rate the sensation of pain on a scale from 0 to100, where 0 represents no pain and 100 represent the worst imaginable pain.
  • Measuring pain by computerized Visual Analog Scale Scoring — Day 2
    We will ask the subjects to rate the sensation of pain on a scale from 0 to100, where 0 represents no pain and 100 represent the worst imaginable pain.
  • Measuring Itch by computerized Visual Analog Scale Scoring — Day 1
    We will ask the subjects to rate the sensation of itch on a scale from 0 to100, where 0 represents no itch and 100 represent the worst imaginable itch.
  • Measuring Itch by computerized Visual Analog Scale Scoring — Day 2
    We will ask the subjects to rate the sensation of itch on a scale from 0 to100, where 0 represents no itch and 100 represent the worst imaginable itch.
  • Alloknesis — Day 1
    Measured using a standardized sensory brush exerting a force of 200 to 400 mN.
  • Alloknesis — Day 2
    Measured using a standardized sensory brush exerting a force of 200 to 400 mN.
  • Mechanically evoked itch (MEI) — Day 1
    MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force).
  • Mechanically evoked itch (MEI) — Day 2
    MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force).
  • Mechanical Pain Thresholds (MPT) — Day 1
    This test is conducted using a pinprick set. The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN.
  • Mechanical Pain Thresholds (MPT) — Day 2
    This test is conducted using a pinprick set. The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN.
  • Mechanical Pain Sensitivity (MPS) — Day 2
    This test is conducted with the same pinprick set used to test the MPT.
  • Mechanical Pain Sensitivity (MPS) — Day 1
    This test is conducted with the same pinprick set used to test the MPT.
  • Pressure Pain Threshold — Day 1
    Pressure pain threshold (PPT) is obtained using a manual pressure algometer
  • Pressure Pain Threshold — Day 2
    Pressure pain threshold (PPT) is obtained using a manual pressure algometer
  • Mechanical Suprathreshold Pain Stimulation — Day 2
    Once PPT has been determined, stimuli of 130% of the PPT will be delivered to the limb or shoulder to create a sensation of subjective mild/moderate pain
  • Computerized Cuff Pressure Algometer (CPA) — Day 1
    A computer-controlled cuff pressure algometer works by inflating a cuff/tourniquet, which is similar in design to those used for measuring blood pressure
  • Spatial and Temporal Summation of Pain — Day 1
    Spatial and temporal summation of pain will be assessed with the use of the computerized cuff pressure algometer
  • Cold Detection Thresholds (CDT) — Day 1
    The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device
  • Cold Detection Thresholds (CDT) — Day 2
    The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device
  • Warm Detection Thresholds (WDT) — Day 1
    The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device
  • Warm Detection Thresholds (WDT) — Day 2
    The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device
  • Cold Pain Thresholds (CPT) — Day 1
    The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device
  • Cold Pain Thresholds (CPT) — Day 2
    The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device
  • Heat Pain Thresholds (HPT) — Day 1
    The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device
  • Heat Pain Thresholds (HPT) — Day 2
    The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device
  • Pain to Supra-threshold Heat Stimuli (STHS) — Day 1
    The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device
  • Pain to Supra-threshold Heat Stimuli (STHS) — Day 2
    The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device
  • EEG recording — Day 1
    The EEG signal will be acquired constantly through 64 electrodes placed on the scalp according to the international 10-20 system with a standard EEG cap
  • Measuring cortical responses to magnetic stimulation — Day 1
    Transcranial magnetic stimulation (TMS) will be used to evoke cortical responses (TMSevoked potentials - TEPs) in the left and right motor cortex with a figure-eight-shaped cone coil (200 pulses for each target).

Trial sites (1)

FacilityCityRegionStatus
Center for Neuroplasticity and Pain Faculty of Medicine, Aalborg University Selma Lagerløfs Vej 249 9260 Gistrup, Denmark Gistrup Aalborg
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07755930 on ClinicalTrials.gov ↗ ← All trials in Denmark